AI assistant
Cellectis — Investor Presentation 2015
Apr 10, 2015
1190_iss_2015-04-10_e516328f-22a6-49e4-8734-d625aa79efc0.pdf
Investor Presentation
Open in viewerOpens in your device viewer
PRESS RELEASE
Cellectis Announces Presentations at Upcoming Conferences
April 9, 2015 – New York (USA) Cellectis S.A. (Alternext: ALCLS – Nasdaq Global Market: CLLS) a pioneering gene-editing company employing proprietary technologies to develop best-in-class products in the emerging field of immunooncology, today announced that Cellectis will be present at the following upcoming conferences:
Cancer Advance Boston
Date: Tuesday, April 14, 2015; presentation time: 1:50PM ET Venue: Joseph B. Martin Conference Center at Harvard Medical School, Boston, Massachusetts
Jefferies Immuno-Oncology Summit
Date: Wednesday, April 15, 2015; presentation time: 11:10AM ET Venue: Boston Harbor Hotel, Boston, Massachusetts
AACR Annual Meeting
Date: Saturday-Wednesday, April 18-22, 2015 Venue: Pennsylvania Convention Center, Philadelphia, Pennsylvania
Bank of America Merrill Lynch 2015 Global Health Care Conference
Date: Tuesday-Thursday, May 12-14, 2015 Venue: Encore at the Wynn, Las Vegas, Nevada
BioEquity Europe
Date: Tuesday-Wednesday, May 19-20, 2015 Venue: Hotel InterContinental, Vienna, Austria
Piper Jaffray GenomeRx Symposium
Date: Wednesday-Thursday, May 20-21, 2015 Venue: The Yale Club, New York, New York
ASCO Annual Meeting
Date: Friday-Tuesday, May 29-June 2, 2015 Venue: McCormick Place, Chicago, Illinois
Jefferies 2015 Healthcare Conference
Date: Monday-Thursday, June 1-4, 2015 Venue: Grand Hyatt, New York City, New York
About Cellectis
Cellectis is a gene-editing company focused on developing immunotherapies based on gene edited engineered CAR-T cells (UCART). The company's mission is to develop a new generation of cancer therapies based on engineered T-cells. Cellectis capitalizes on its 15 years of expertise in genome engineering - based on its flagship TALEN™ products and meganucleases and pioneering electroporation PulseAgile technology - to create a new generation of immunotherapies. CAR technologies are designed to target surface antigens expressed on cells. Using its life-science-focused, pioneering genomeengineering technologies, Cellectis' goal is to create innovative products in multiple fields and with various target markets. Cellectis S.A. is listed on the Nasdaq Global Market (ticker: CLLS) and on the NYSE Alternext market (ticker: ALCLS). To find out more about us, visit our website: www.cellectis.com
For further information, please contact:
Cellectis
Simon Harnest, VP Finance and Investor Relations Phone: +1 646 385-9008 email: [email protected]
Jennifer Moore, Director of Communications Phone: +1 917 580-1088 email: [email protected]